Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Darpö, B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Darpö, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes

B. Darpö*

Department of Cardiology, Karolinska Hospital, Stockholm, and Quintiles Services, Stockholm, Sweden

* Correspondence: Börje Darpö, MD, Associate Professor, Quintiles Services, Hornsbergsg. 17, SE-11251, Stockholm, Sweden.

Abstract

The incidence of drug-induced proarrhythmias in the general population is largely unknown. Knowledge regarding incidence and risk factors is mainly derived from studies during clinical development of drugs and is therefore limited to antiarrhythmic compounds with a relatively high incidence. For non-cardiovascular drugs, proarrhythmias are rarely seen during clinical development but usually appear later, several years after registration. Both spontaneous adverse reaction reports and epidemiological studies have severe limitations when used to estimate the incidence of proarrhythmias with non-cardiovascular compounds. QT prolongation and torsades de pointes have been associated with non-sedating antihistamines, antibiotics, antipsychotics, antidepressants and a gastrointestinal prokinetic agent; drugs within these classes constitute the vast majority of non-cardiovascular compounds associated with this potentially serious side-effect. Epidemiological studies on non-sedating antihistamines and on cisapride have largely failed to demonstrate an increased risk for sudden death or ventricular arrhythmias, which is most likely due to the low specificity of the end-points studied. A careful case ascertainment, which requires access to electrocardiograms and clinical records, and prospectively defined, strict definitions for the classification of proarrhythmias, is of great importance in these studies.

Key Words: Torsades de pointes • QT prolongation • noncardiovascular drugs • epidemiology

References

  1. Wiholm B-E, Olsson S, Moore N, Waller P. Spontaneous reporting systems outside the US. Strom BL. Pharmacoepidemiology. 2nd edn. Chichester, U.K.,: John B Wiley & Sons Ltd; 1994.
  2. Barbey IT, Lazzara R, Zipes DP. Review of spontaneous adverse event reports of serious ventricular arrhythmias QT prolongation, syncope, and sudden death in patients treated with Ciapride. Circulation. 1999;100:I–308
  3. Roden DM. Taking the ‘idio’ out of ‘idiosyncratic’: predicting torsades de pointes. [editorial]Pacing Clin Electrophysiol. 1998;21:1029–1034[CrossRef][Medline]
  4. Wysowski DK, Bacsanyi J. Cipapride and fatal arrhythmia. [letter]N Engl J Med. 1996;335:290–291[Free Full Text]
  5. Steinbeck G, Remp T, Hoffmann E. Effects of Class I drugs on atrial fibrillation. J Cardiovasc Electrophysiol. 1998;9:S104–S108[Web of Science][Medline]
  6. Coplen SE, Antan EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-C analysis of randomized control trials. Circulation. 1990;82:1106–1116[Abstract/Free Full Text]
  7. Sihm I, Hansen FA, Rasmussen J, Pedersen AK, Thygesen K. Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects. Eur Heart J. 1990;11:145–148[Abstract/Free Full Text]
  8. Greene HL, Roden DM, Katz RJ, Woosley RL, Salemo DM, Henthom RW. The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. J Am Coll Cardiol. 1992;19:894–898[Abstract]
  9. Podrid PL, Anderson JL. Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group. Am J Cardiol. 1996;78:430–434[CrossRef][Web of Science][Medline]
  10. Radford MD, Evans DW. Long-term results of DC reversion of atrial fibrillation. Br Heart J. 1968;30:91–96[Free Full Text]
  11. Cramer G. Early and late results of conversion of atrial fibrillation with quinidine. A clinical and hemodynamic study. Acta Med Scand Suppl. 1968;490:5–102[Medline]
  12. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J. 1986;111:1088–1093[CrossRef][Web of Science][Medline]
  13. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis. 1988;31:115–172[CrossRef][Web of Science][Medline]
  14. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781–788[Abstract]
  15. Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med. 1994;331:785–791[Free Full Text]
  16. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 1992;20:527–532[Abstract]
  17. Jafari-Fesharaki M, Scheinman MM. Adverse effects of amiodarone. Pacing Clin Electrophysiol. 1998;21:108–120[CrossRef][Medline]
  18. Capucci A, Lenzi T, Boriani G, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol. 1992;70:69–72[CrossRef][Web of Science][Medline]
  19. Kerin NZ, Faitel K, Naini M. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation. Arch Intern Med. 1996;156:49–53[Abstract/Free Full Text]
  20. Galve E, Rius T, Ballester R, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol. 1996;27:1079–1082[Abstract]
  21. Boriani G, Cappucci A, Botto G, et al. Different pharmacologic treatment for converting recent-onset atrial fibrillation: Evaluation on 377 patients. (Abstr)J Am Coll Cardiol. 1996;27(Suppl A):80A
  22. Kochiadakis GE, Igoumenidis NE, Solomon MC, et al. Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion. Cardiovasc Drugs Ther. 1998;12:75–81[CrossRef][Web of Science][Medline]
  23. Kochiadakis GE, Igoumenidis NE, Parthenakis FI, Chlouverakis GI, Vardas PE. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol. 1999;33:966–971[Abstract/Free Full Text]
  24. Vardas PE, Kochiadakis GE, Igoumenidis NE, Tsatsakis AM, Simantirakis EN, Chlouverakis GI. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: A randomized, controlled study. [in Process Citation]Chest. 2000;117:153–1545
  25. Sung RJ, Tan HL, Karagounis L, et al. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double blind, placebo-controlled study. Sotalol Multicenter Study Group. Am Heart J. 1995;129:739–748[CrossRef][Web of Science][Medline]
  26. Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart. 1998;79:568–575[Abstract/Free Full Text]
  27. Reisinger J, Gatterer E, Heinze G, et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol. 1998;81:1450–1454[CrossRef][Web of Science][Medline]
  28. Chung MK, Schweikert RA, Wilkoff BL, et al. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol. 1998;32:169–176[Abstract/Free Full Text]
  29. Suttorp MJ, Polak PE, van 't Hof A, Rasmussen HS, Dunselman PR, Kingma JH. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. Am J Cardiol. 1992;69:417–419[CrossRef][Web of Science][Medline]
  30. Bianconi L, Dinelli M, Pappalardo A, et al. Comparison of intravenously-administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicenter, randomized, double-blind placebo-controlled study. (Abstr)Circulation. 1995;92(Suppl I):I–774
  31. Sedgwick ML, Lip G, Rae AP, Cobbe SM. Chemical cardioversion of atrial fibrillation with intravenous dofetilide. Int J Cardiol. 1995;49:159–166[CrossRef][Web of Science][Medline]
  32. Green M, Dorian P, Roy D, et al. A randomized, doubleblind, placebo-controlled comparison of intravenous dofetilide and procainamide in the acute conversion of atrial flibrillation/flutter. (Abstr)Circulation. 1997;96:I–453 (Suppl)
  33. Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol. 1997;29:385–390[Abstract]
  34. Norgaard BL, Wachtell K, Christensen PD, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am Heart J. 1999;137:1062–1069[CrossRef][Web of Science][Medline]
  35. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol. 1996;28:130–136[Abstract]
  36. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation. 1996;94:1613–1621[Abstract/Free Full Text]
  37. Crijns HJGM, Golitsyn SR, Ruda MY, et al. Superiority of ibutilide over dl-sotalol in termination of atrial fibrillation and flutter: results of a multinational trial. (Abstr)Eur Heart J. 1996;17:583[Abstract/Free Full Text]
  38. Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol. 1998;31:1414–1419[Abstract/Free Full Text]
  39. Abi-Mansour P, Carberry PA, McCowan RJ, Henthorn RW, Dunn GH, Perry KT. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators. Am Heart J. 1998;136:632–642[CrossRef][Web of Science][Medline]
  40. Darpo B, Edvardsson N. Effect of almokalant, a selective potassium channel blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias: a study in patients with Wolf-Parkinson-White syndrome and atrioventricular nodal reentrant tachycardia. Almokalant PSVT Study Group. J Cardiovasc Pharmacol. 1995;26:198–206[Web of Science][Medline]
  41. Houltz B, Darpo B, Edvardsson N, et al. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. Pacing Clin Electrophysiol. 1998;21:1044–1057[CrossRef][Medline]
  42. Stewart DA, Taylor J, Ghosh S, et al. Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur J Clin Pharmacol. 1992;42:577–580[Web of Science][Medline]
  43. Connolly MJ, Astridge PS, White EG, Morley CA, Cowan JC. Torsades de pointes ventricular tachycardia and terodiline. Lancet. 1991;338:344–345[CrossRef][Web of Science][Medline]
  44. Manouvrier J, Sagot M, Caron C, et al. Nine cases of torsade de pointes with bepridil administration. Am Heart J. 1986;111:1005–1007[CrossRef][Web of Science][Medline]
  45. Pinaud D, Chabanier A, Vergnoux H, et al. Bepridil and torsades de pointes. Apropos of 11 cases. Ann Cardiol Angeiol (Paris). 1987;36:421–425
  46. SoRelle R. Withdrawal of Posicor from market. [news]Circulation. 1998;98:831–832[Free Full Text]
  47. Levine TB, Bernink PJ, Caspi A, et al. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial. Circulation. 2000;101:758–764[Abstract/Free Full Text]
  48. Simmons FE, Kesselman MS, Giddins NG, Pelech AN, Simons KJ. Astemizole-induced torsade de pointes. [letter]Lancet. 1988;2:624[Web of Science][Medline]
  49. Davies AJ, Harindra V, McEwan A, Ghose RR. Cardiotoxic effect with convulsions in terfenadine overdose. Br Med J. 1989;298:325
  50. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr.. Torsades de pointes occurring in association with terfenadine use. J Am Med Assoc. 1990;264:2788–2790[Abstract/Free Full Text]
  51. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. J Am Med Assoc. 1993;269:1513–1518[Abstract/Free Full Text]
  52. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. J Am Med Assoc. 1993;269:1532–1536[Abstract/Free Full Text]
  53. Pratt CM, Hertz RP, Ellis BE, Crowell SP, Louv W, Moye L. Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. Am J Cardiol. 1994;73:346–352[CrossRef][Web of Science][Medline]
  54. Hanrahan JP, Choo PW, Carlson W, Greineder D, Faich GA, Platt R. Terfenadine-associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenance organization. Ann Epidemiol. 1995;5:201–209[CrossRef][Medline]
  55. Staffa JA, Jones JK, Gable CB, Verspeelt JP, Amery WK. Risk of selected serious cardiac events among new users of antihistamines. Clin Ther. 1995;17:1062–1077[CrossRef][Web of Science][Medline]
  56. de Abajo FL, Rodriguez LA. Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. Br J Clin Pharmacol. 1999;47:307–313[CrossRef][Web of Science][Medline]
  57. Lindquist M, Edwards IR. Risks of non-sedating antihistamines. [letter]Lancet. 1997;349:1322[Web of Science][Medline]
  58. Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Exp Ther. 1997;282:220–227[Abstract/Free Full Text]
  59. Walker AM, Szneke P, Weatherby LB, et al. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med. 1999;107:356–362[CrossRef][Web of Science][Medline]
  60. Ebert SN, Liu XK, Woosley RL. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health. 1998;7:547–557[Web of Science][Medline]
  61. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1996;111:383–390
  62. Kannel WB, Gagnon DR, Cupples LA. Epidemiology of sudden coronary death: population at risk. Can J Cardiol. 1990;6:439–444[Web of Science][Medline]
  63. Antzelevitch C, Sun ZQ, Zhang ZQ, Yan GX. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol. 1996;28:1836–1848[Abstract]
  64. Gitler B, Berger LS, Buffa SD. Torsades de pointes induced by erythromycin. Chest. 1994;105:368–372[Abstract/Free Full Text]
  65. Chennareddy SB, Siddique M, Karim MY, Kudesia V. Erythromycin-induced polymorphous ventricular tachycardia with normal QT interval. Am Heart J. 1996;132:691–694[CrossRef][Web of Science][Medline]
  66. Katapadi K, Kostandy G, Katapadi M, Hussain KM, Schifter D. A review of erythromycin-induced malignant tachyarrhythmia—torsade de pointes. A case report. Angiology. 1997;48:821–826
  67. Drici MD, Knollmann BC, Wang WX, Woosley RL. Cardiac actions of erythromycin: influence of female sex. J Am Med Assoc. 1998;280:1774–1776[Abstract/Free Full Text]
  68. Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI. Proarrhythmia associated with cisapride in children. Pediatrics. 1998;101:1053–1056[Abstract/Free Full Text]
  69. Lee KL, Jim MH, Tang SC, Tai YT. QT prolongation and Torsades de Pointes associated with clarithromycin. Am J Med. 1998;104:395–396[CrossRef][Web of Science][Medline]
  70. Sekkarie MA. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am J Kid Dis. 1997;30:437–439[Web of Science][Medline]
  71. Jaillon P, Morganroth J, Brumpt I, Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. J Antimicrob Chemother. 1996;37:161–167[Abstract/Free Full Text]
  72. Stahlmann R, Lode H. Toxicity of quinolones. Drugs. 1999;58:37–42
  73. Ball P. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother. 2000;45:557–559[Free Full Text]
  74. Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH. The cardiac pharmacodynamics of therapeutic doses of sparfloxacin. Clin Ther. 1999;21:1171–1181[CrossRef][Web of Science][Medline]
  75. Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf. 1999;21:407–421[CrossRef][Web of Science][Medline]
  76. Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000;59:115–139[CrossRef][Web of Science][Medline]
  77. The Pink Sheet — Prescription Pharmaceutical and Biotechnology. 1999;61:15–16
  78. Dumaine R, Roy ML, Brown AM. Blockade of HERG and Kv1.5 by ketoconazole. J Pharmacol Exp Ther. 1998;286:727–735[Abstract/Free Full Text]
  79. Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira IN, Peter T. QT prolongation and torsades de pointes after administration of trimethoprim- sulfamethoxazole. Am J Cardiol. 1987;59:376–377[CrossRef][Web of Science][Medline]
  80. Wiener I, Rubin DA, Martinez E, Postman J, Herman MY. QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim sulfamethoxazole administration. Mt Sinai J Med. 1981;48:53–55[Medline]
  81. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol. 1983;5:173–175[Web of Science][Medline]
  82. Martin ES, Rogalski K, Black JN. Quinine may trigger torsades de pointes during astemizole therapy. Pacing Clin Electrophysiol. 1997;20:2024–2025[CrossRef][Medline]
  83. Monlun E, Pillet O, Cochard IF, Favarel Garrigues JC, le Bras M. Prolonged QT interval with halofantrine. [letter; comment]Lancet. 1993;341:1541–1542[Web of Science][Medline]
  84. Toivonen L, Viitasalo M, Siikamaki H, Raatikka M, Pohjola-Sintonen S. Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QT syndrome. Clin Cardiol. 1994;17:403–404[Web of Science][Medline]
  85. Otsuka M, Kanamori H, Sasaki S, et al. Torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in acute myelogenous leukemia. Intern Med. 1997;36:705–708[Web of Science][Medline]
  86. Olree K, Stein-Gocken J. Torsade de pointes and elevated magnesium and calcium requirements associated with intravenous pentamidine. Nutr Clin Pract. 1994;9:191–195[Abstract/Free Full Text]
  87. Harel Y, Scott WA, Szeinberg A, Barzilay Z. Pentamidine-induced torsades de pointes. Pediatr Infect Dis J. 1993;12:692–694[CrossRef]
  88. Warner JP, Barnes TR, Henry JA. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand. 1996;93:311–313[Web of Science][Medline]
  89. Buckley NA, White IM, Dawson AH. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol. 1995;33:199–204[Web of Science][Medline]
  90. Thomas SH, Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Drug React Toxicol Rev. 1994;13:77–102[Web of Science][Medline]
  91. Jackson T, Ditmanson L, Phibbs B. Torsade de pointes and low-dose oral haloperidol. Arch Intern Med. 1997;157:2013–2015[Abstract/Free Full Text]
  92. Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy. 1997;17:531–537[Web of Science][Medline]
  93. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355:1048–1052[CrossRef][Web of Science][Medline]
  94. Drolet B, Vincent F, Rail J, et al. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther. 1999;288:1261–1268[Abstract/Free Full Text]
  95. Drolet B, Zhang S, Deschenes D, et al. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol. 1999;10:1597–1604[Web of Science][Medline]
  96. Krahenbuhl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PL. Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication. Am J Med Sci. 1995;309:315–316[Web of Science][Medline]
  97. Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther. 1999;65:10–20[CrossRef][Web of Science][Medline]
  98. Cutler NR, Sramek J. Atypical antipsychotics and QT prolongation: A class effect. Current Opinion in CPNS Investigational Drugs. 2000;2:52–57
  99. Drici MD, Wang WX, Liu XK, Woosley RL, Flockhart DA. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol. 1998;18:477–481[CrossRef][Web of Science][Medline]
  100. Welch R, Chue P. Antipsychotic agents and QT changes. J Psychiatry Neurosci. 2000;25:154–160[Web of Science][Medline]
  101. Litherland S. Drug treatment and schizophrenia in the 1990s. Drugs. 1997;54:794[Web of Science][Medline]
  102. Liljegvist JA, Edvardsson N. Torsade de pointes tachycardias induced by overdosage of zimeldine. J Cardiovasc Pharmacol. 1989;14:666–670[Web of Science][Medline]
  103. Personne M, Sjoberg G, Persson H. Citalopram overdose—review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol. 1997;35:237–240[Web of Science][Medline]
  104. Grundemar L, Wohlfart B, Lagerstedt C, Bengtsson F, Eklundh G. Symptoms and signs of severe citalopram overdose. [letter]Lancet. 1997;349:1602[Web of Science][Medline]
  105. Callaham M, Kassel D. Epidemiology of fatal tricyclic antidepressant ingestion: implications for management. Ann Emerg Med. 1985;14:1–9[CrossRef][Web of Science][Medline]
  106. Dorsey ST, Biblo LA. Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med. 2000;18:227–229[CrossRef][Web of Science][Medline]
  107. Casazza F, Fiorista F, Rustici A, Brambilla G. Torsade de pointes caused by tricyclic antidepressive agents. Description of a clinical case. G Ital Cardiol. 1986;16:1058–1061[Medline]
  108. Herrmann HC, Kaplan LM, Bierer BE. Q-T prolongation and torsades de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. Am J Cardiol. 1983;51:904–906[CrossRef][Web of Science][Medline]
  109. Baker B, Dorian P, Sandor P, et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol. 1997;17:15–21[CrossRef][Web of Science][Medline]
  110. Strasberg B, Coelho A, Welch W, Swiryn S, Bauernfeind R, Rosen K. Doxepin induced torsade de pointes. Pacing Clin Electrophysiol. 1982;5:873–877[CrossRef][Medline]
  111. Appleby M, Mbewu A, Clarke B. Fluoxetine and ventricular torsade—is there a link? [letter]Int J Cardiol. 1995;49:178–180[CrossRef][Web of Science][Medline]
  112. Lherm T, Lottin F, Larbi D, Bray M, Legall C, Caen D. Torsade de pointes after poisoning with fluoxetine alone. Presse Med. 2000;29:306–307
  113. Trump DL, Smith DC, Ellis PG, et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst. 1992;84:1811–1816[Abstract/Free Full Text]
  114. Liu XK, Katchman A, Ebert SN, Woosley RL. The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes. J Pharmacol Exp Ther. 1998;287:877–883[Abstract/Free Full Text]
  115. Klein L. QT-interval prolongation produced by probucol. Arch Intern Med. 1981;141:1102–1103[Abstract/Free Full Text]
  116. Browne KF, Prystowsky EN, Heger JJ, Cerimele BJ, Fineberg N, Zipes DP. Prolongation of the QT interval induced by probucol: demonstration of a method for deter mining QT interval change induced by a drug. Am Heart J. 1984;107:680–684[CrossRef][Web of Science][Medline]
  117. Reinoehl J, Frankovich D, Machado C, et al. Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am Heart J. 1996;131:1184–1191[CrossRef][Web of Science][Medline]
  118. Hodak SP, Moubarak JB, Rodriguez I, Gelfand MC, Alijani MR, Tracy CM. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. Transplantation. 1998;66:535–537[CrossRef][Web of Science][Medline]
  119. Minematsu T, Ohtani H, Sato H, Iga T. Sustained QT prolongation induced by tacrolimus in guinea pigs. Life Sci. 1999;65:L197–L202[CrossRef]
  120. Kleinsasser A, Kuenszberg E, Loeckinger A, et al. Sevoflurane, but not propofol, significantly prolongs the Q-T interval. Anesth Analg. 2000;90:25–27[Abstract/Free Full Text]
  121. Michaloudis D, Fraidakis O, Lefaki T, Kanakoudis F, Askitopoulou H. Anaesthesia and the QT interval in humans: effects of halothane and isoflurane in premeditated children. Eur J Anaesthesiol. 1998;15:623–628[Web of Science][Medline]
  122. Bryer-Ash M, Zehnder J, Angelchik P, Maisel A. Torsades de pointes precipitated by a Chinese herbal remedy. Am J Cardiol. 1987;60:1186–1187[CrossRef][Web of Science][Medline]
  123. Eriksson JW, Carlberg B, Hillorn V. Life-threatening ventricular tachycardia due to liquorice-induced hypokalaemia. J Intern Med. 1999;245:307–310[CrossRef][Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NEJMHome page
W. A. Ray, C. P. Chung, K. T. Murray, K. Hall, and C. M. Stein
Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death
N. Engl. J. Med., January 15, 2009; 360(3): 225 - 235.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Darpö, B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Darpö, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?